Ranked #1 Children's Hospital by U.S. News & World Report
MyPatients provides referring primary care providers with secure access to their patients’ information.
Boston Children's has launched the world's 1st program dedicated to offering hand transplants to children who qualify.
Innovation insider is a semi-monthly e-newsletter analyzes innovations at Boston Children’s, other academic medical centers and from industry.
Read the latest blog by a Boston Children's doctor, clinician or staff member.
Support the hospital with a donation that helps kids get the care they need.
Juvenile myasthenia gravis (JMG) is the childhood form of myasthenia gravis (MG), and is an autoimmune disease in which a child’s body produces antibodies that attack the acetylcholine receptor and sometimes other proteins at the neuromuscular junction. Acetylcholine is a neurotransmitter that plays a key role in muscle contractions. Not having enough receptor sites for acetylcholine causes a child’s muscles to weaken over time.
Here’s what you need to know about JMG:
How Boston Children’s Hospital approaches JMG:
Since 1977, thousands of children have been successfully diagnosed and treated at the Neuromuscular Center where they are evaluated and treated by a team of world-renowned experts in child neurology, orthopedics and genetics.
The Department of Ophthalmology and the Pediatric Ophthalmology Program at Boston Children’s also uses both medical and surgical approaches to treat a wide range of eye conditions caused by neurological disorders such as myasthenia gravis. We use the most advanced diagnostic and treatment methods available and incorporate minimally invasive techniques whenever possible.
Our teams will work together with your family to develop treatment plans that meet your child's unique needs and provide him with the best possible quality of life.
Myasthenia gravis: Reviewed by Peter Kang, MD © Boston Children’s Hospital, 2011
The future of pediatrics will be forged by thinking differently, breaking paradigms and joining together in a shared vision of tackling the toughest challenges before us.”